Weight recurrence following metabolic and bariatric surgery (MBS) represents a clinically significant challenge that reflects the chronic and relapsing nature of obesity. Although revisional bariatric surgery has traditionally been considered the primary treatment option for affected patients, it is associated with greater technical complexity and higher complication rates than primary procedures. The emergence of highly effective incretin-based pharmacotherapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA tirzepatide, has substantially broadened the treatment options available for this population. This review examines the epidemiology, pathophysiology, and clinical evaluation of post-operative weight recurrence and explores the evolving role of incretin-based therapies as potential alternatives or adjuncts to revisional bariatric surgery. Current evidence indicates that post-operative weight recurrence is multifactorial, arising from neurohormonal adaptation, behavioral factors, metabolic compensation, and anatomical changes. Randomized trials, systematic reviews, meta-analyses, and observational studies consistently demonstrate that GLP-1 RAs can achieve clinically meaningful weight loss in patients with insufficient weight loss or post-operative weight recurrence, particularly in the absence of correctable anatomical abnormalities. Tirzepatide has demonstrated greater weight-loss efficacy than earlier incretin-based therapies and may represent an important therapeutic option for appropriately selected post-bariatric patients. Emerging agents, including triple-RAs, GLP-1/glucagon dual agonists, and oral GLP-1 RAs, may further expand future treatment options. Collectively, the available evidence supports a multidisciplinary, step-wise management strategy incorporating anatomical assessment, lifestyle optimization, and evidence-based pharmacotherapy before consideration of revisional surgery. While revisional procedures remain essential for patients with anatomical failure, modern incretin-based therapies may reduce, delay, or better select the need for revisional surgery in appropriately evaluated patients. Further prospective studies are needed to define their long-term role within post-bariatric treatment algorithms.
